Pharma Giants Strike Deal with Trump to Cut US Drug Prices
Agreement Overview and Key Participants
In a significant move affecting the pharmaceutical landscape, US President Donald Trump has announced a new initiative aimed at reducing prescription drug prices for Americans. This initiative involves agreements with nine major pharmaceutical companies to drastically cut prices on various medications sold in the United States. The companies involved in this deal include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
Elimination of Global Subsidization
At a recent press conference, Trump stated, “We were subsidizing the entire world. We’re not doing it anymore,” highlighting a shift in US policy regarding pharmaceutical pricing. The White House has confirmed that these agreements will ensure that foreign countries can no longer utilize price controls to benefit from American pharmaceutical innovation. This approach promises to align US drug prices with the lowest prices paid in other developed nations, a concept referred to as the most-favoured-nation (MFN) price.
Price Reductions Across Multiple Medications
The announced agreements will result in substantial reductions in the prices of numerous essential medications. The White House provided examples of these reductions, which illustrate the potential impact on consumers and healthcare expenses.
- Amgen’s cholesterol medication, Repatha, will see its price drop from $573 to $239.
- Bristol Myers Squibb’s HIV treatment, Reyataz, will be reduced from $1,449 to $217.
- Boehringer Ingelheim’s type 2 diabetes drug, Jentadeuto, will be slashed from $525 to $55.
- Gilead Sciences’ Hepatitis C treatment, Epclusa, will go from $24,920 to $2,425.
- Merck’s diabetes medication, Januvia, will see a decrease from $330 to $100.
- Novartis’ Multiple Sclerosis medication, Mayzent, will be lowered from $9,987 to $1,137.
- Sanofi’s blood thinner, Plavix, will be available at $16, down from $756, along with its insulin products priced at $35 per month’s supply.
These reductions represent a striking shift in the pricing structure for critical medications in the US market.
Terms of Engagement and Future Implications
The agreements mutually benefit both the pharmaceutical companies and the US government. Under this arrangement, drug manufacturers will be required to launch new medications at prices comparable to those in other wealthy nations. Furthermore, the deal includes provisions for cutting cash-pay prices for select drugs to enhance affordability for consumers.
In return for the price cuts, participating companies will receive a three-year exemption from any tariffs, promoting continued collaboration and innovation within the industry. This framework has been established to encourage pharmaceutical giants to invest more in research and development, as well as manufacturing within the US.
Response from the Pharmaceutical Industry
This strategic approach is the latest in a series of initiatives aimed at lowering prescription drug costs, a persistent issue for many Americans. Trump has previously communicated with key figures in the pharmaceutical industry, urging them to adopt MFN pricing for Medicaid and ensuring new medications are launched at competitive prices.
Notably, five pharmaceutical companies have already entered similar agreements with the administration, including Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and the US division of Merck KGaA, EMD Serono. Three additional companies, Regeneron, Johnson & Johnson, and AbbVie, have yet to finalize agreements under this framework.
Commitment to Research and Development
The participating companies have collectively pledged more than $150 billion in investment within the United States, focusing on research and development as well as manufacturing. This investment is intended to bolster the domestic pharmaceutical industry while ensuring that American patients have access to the most innovative treatments available.
The agreements mark a pivotal moment in US healthcare policy, emphasizing a focus on lowering drug costs for consumers while maintaining a robust pharmaceutical industry capable of delivering cutting-edge medical innovations.
Published on 1766254188 • Category: Americas,pharma